Big Pharma is everything but shy when it comes to lobbying EU policy-makers. But what exactly are these groups lobbying for in TTIP?
According to the Bloomberg, Senator Hatch said “They’re going to have to find a way of having the countries agree to change that formality in the TPP to 12 years…If Australia wants to be part of it, they have to meet our terms,”
As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam, humanitarian aid organisation Médecins Sans Frontières calls for the removal of intellectual property provisions from the agreement
Provisions related to evergreening of patents in the proposed Regional Comprehensive Economic Partnership Agreement (RCEP) was dropped after stiff opposition from India, Parliament was informed today.
Adopting a national pharmacare program would offset the higher drug prices expected with the ratification of the Trans-Pacific Partnership, write Tanishq Suryavanshi and Jake Hirsch-Allen.
We call on countries negotiating the RCEP agreement and to protect the flexibilities available under the WTO TRIPS agreement for Least Developed Countries (LDCs).
A high-level panel hosted by India discusses the issues of trade deals that inhibit access to medicines and also limit policy space for governments to legislate in public interest.
The Ministry of Commerce must be cautious of Free Trade Agreements being negotiated with the European Union as well as the Regional Comprehensive Economic Partnership that further strengthen or extend intellectual property (IP) monopolies.
Of the RCEP negotiating countries, it is India, rather than China, that has been the most outspoken in opposing US-style trade rules.
The letter says that this dispute over the compulsory license could prejudice resources for a new initiative called "Paz Colombia", as well as the US FTA with Colombia, and access to the TPP.
Access to affordable medicines could be severely restricted for millions of people around the world under the current proposals in the Regional Comprehensive Economic Partnership (RCEP) trade agreement?
Signing the TPP has provoked a debate on whether, when it comes into force, there will be a potential spike in medicines prices.
The historic decision to break barriers to improve access to costly medicines was taken during the “First Extraordinary Meeting of the Ministers of the Common Market of the South (Mercosur).
One element of TTIP has been largely ignored – the deal’s impact on developing countries.
India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers.
Revision of the legal framework on intellectual property is recommended to ensure compliance with the EU – Viet Nam Free Trade Agreement.
It’s no joke. The consequence that the Transpacific Treaty on Economic Cooperation (the English acronym for which is the TPP) recently signed by 12 countries in the Pacific Ocean, including Mexico, Peru and Chile on this side of the Pond, has on access to medicines is brutal.
"The battle to prevent this trade agreement from being implemented is far from over", asserts the humanitarian organization, joining the rejection that the treaty Chile signed in New Zealand arouses.
One immediate obstacle to getting the Trans-Pacific Partnership through US Congress lives in Jan Kemper’s laboratory an hour’s drive from the White House.
Deal’s fate rests on ‘talks about talks’ between senior officials as EU demands greater flexibility on imports.